Coartem® Dispersible

Novartis

Product category
  • Artemisinin-based Combination Therapy (ACT)

  • Artemether-lumefantrine

Therapeutic indication
  • Treatment of children >5kg and <25kg with uncomplicated P. falciparum infection (including mixed infection)

Dosing
  • Twice-daily for 3 days

Efficacy
  • 28-day cure rate (PCR-corrected) 94%–98%
  • 42-day cure rate (PCR-corrected) 96%–100%

Key features
  • Dispersible, cherry-flavour taste-masked formulation dissolves in 10ml of water, eases paediatric administration

Challenges
  • Food effect: should be taken with food or drink rich in fat

  • Twice-daily dosing

Status
  • Approved 2008 SwissMedic; 2012 EMA

  • Approved in over 50 endemic countries (see map)

  • >385 million treatments distributed

MMV Project Director
  • Adam Aspinall